Dr. Timothy Pardee, M.D., PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
1 Medical Center Blvd, Hanes Bld. Rm 4046
Winston Salem, NC 27157
- Medicare participating
At a glance
- Medical school
- State University of New York at Buffalo School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 80
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: State University of New York at Buffalo School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NC license 2009-00253 · NY license 236049
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Carolina Baptist Hospital Winston-Salem, NC
- Wilkes Regional Medical Center North Wilkesboro, NC
Medical groups
- Wake Forest University Health Sciences (2,645 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 340
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 154 | 37 |
| Established patient office or other outpatient visit, 30-39 minutes | 130 | 41 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 30 | 15 |
| Hospital discharge day management, 30 minutes or less | 25 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Levofloxacin Other prescribers in Winston Salem, NC | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 6 payments worth $11,745 in total to this clinician.
| Ipsen Innovation | $9,095 |
|---|---|
| Syndax Pharmaceuticals, Inc. | $2,650 |
| Consulting Fee | $11,695 |
|---|---|
| Food and Beverage | $50.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Ipsen Innovation Dec 19, 2025 | Consulting Fee | $2,745 |
| Ipsen Innovation Apr 15, 2025 | Consulting Fee | $2,710 |
| Syndax Pharmaceuticals, Inc. Dec 5, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,600 |
| Ipsen Innovation Sep 3, 2025 | Consulting Fee | $1,820 |
| Ipsen Innovation Sep 12, 2025 | Consulting Fee | $1,820 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $254,911 in research payments for these studies, mostly to the institutions running them.
- An Investigator-Sponsored Randomized Phase II Study of Selinexor in Combination with Induction Consolidation Maintenance Therapy in Older AML Patients Wake Forest Baptist Comprehensive Cancer Center (WFBCCC)
Karyopharm Therapeutics Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555 - A phase 1, open-label, dose-escalation, and dose-expansion study to evaluate safety, tolerability, and clinical activity OFSNDX-5613IN combination with intensive chemotherapy in participants with newly diagnosed acute…
Syndax Pharmaceuticals, Inc. - A Phase 4, Multi-center Open-label Feasibility Study to Evaluate Outpatient Blinatumomab Administration in Adult Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL) in Comple…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.